Maxim Pharmaceutical Phase 3 Trial for Advanced Malignant Melanoma Fails to Meet Primary Endpoint
20 sept. 2004 02h07 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Sept. 20, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that its confirmatory Phase 3 trial (M104) of the investigational drug...
Maxim Pharmaceuticals Announces 2004 Third Quarter Financial Results
03 août 2004 02h02 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Aug. 3, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today announced results for the quarter ended June 30, 2004, the third quarter of its...
Maxim Pharmaceuticals Announces Appointment of Richard A. Mafrica as Vice President Commercialization
27 juil. 2004 01h53 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, July 27, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced the appointment of Richard A. Mafrica, 47, to the newly created position...
Maxim Pharmaceuticals Added to Russell 2000 Index
29 juin 2004 02h09 HE
|
Maxim Pharmaceuticals
SAN DIEGO, June 29, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced that its stock has been added to the Russell 2000 Index.
The annual reconstitution of Russell's 21...
Maxim Pharmaceuticals Added to Nasdaq Biotechnology Index
25 mai 2004 03h07 HE
|
Maxim Pharmaceuticals
SAN DIEGO, May 25, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that it has been added to the NASDAQ Biotechnology Index(r) (NBI). All securities in the Index...
Maxim Pharmaceuticals Announces Final Dismissal Of Federal Lawsuit
20 mai 2004 08h36 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, May 20, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) announced that the Plaintiff in the Company's federal class action securities complaint has dropped...
Maxim Pharmaceuticals Presents New Preclinical Results Showing Prevention Of Liver Injury By Histamine
18 mai 2004 03h12 HE
|
Maxim Pharmaceuticals
SAN DIEGO and STOCKHOLM, Sweden, May 18, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced preclinical results demonstrating the ability of histamine to prevent...
Maxim Pharmaceuticals Announces Phase 3 Trial of Ceplene in Acute Myeloid Leukemia Meets Primary Trial Endpoint
12 mai 2004 03h06 HE
|
Maxim Pharmaceuticals
San Diego, Calif. and STOCKHOLM, Sweden, May 12, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced the results of an international Phase 3 clinical trial testing the...
Maxim Pharmaceuticals Announces 2004 Second Quarter Financial Results
04 mai 2004 03h21 HE
|
Maxim Pharmaceuticals
SAN DIEGO, Calif., and STOCKHOLM, Sweden, May 4, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today announced results for the quarter ended March 31, 2004, the second...
Maxim Pharmaceuticals Presents Preclinical Data on Histamine's Ability to Prevent Liver Damage
19 avr. 2004 03h23 HE
|
Maxim Pharmaceuticals
SAN DIEGO, April 19, 2004 - Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced preclinical results indicating that histamine may prevent lipopolysaccharide (LPS)-induced liver injury. The...